Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit - PubMed (original) (raw)
Comparative Study
. 2012 Dec;110(11 Pt B):E596-600.
doi: 10.1111/j.1464-410X.2012.11326.x. Epub 2012 Jul 3.
Affiliations
- PMID: 22758907
- DOI: 10.1111/j.1464-410X.2012.11326.x
Comparative Study
Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit
Sarfraz Ahmad et al. BJU Int. 2012 Dec.
Abstract
What's known on the subject? and What does the study add? The idea of using photosensitizing agents to enhance visualization of cancer tissue dates back to 1900. 5-Aminolevulinic acid (5-ALA) was first suggested for photodynamic diagnosis (PDD) of transitional cell cancer (TCC) of the bladder in 1992. Since then, PDD with intravesical application of 5-ALA or its ester hexaminolevulinate (Hexvix) has proven to be superior over standard white-light cystoscopy in detection of carcinoma in situ and dysplasia as well as enhancing margins of TCC. PDD of upper urinary tract TCC is under-studied because of trouble with delivery of the photosensitizer. Fluorescence after oral 5-ALA was initially reported in 1956. Oral 5-ALA for photodynamic therapy was suggested for upper urinary tract TCC in 1998 and for refractory non-muscle invasive bladder cancer in 2001. A study in 2012 on oral and intravesical application of 5-ALA for bladder PDD showed no difference in diagnostic accuracy for each modality. To our knowledge our series is the first report on use of oral 5-ALA for PDD in detection of upper urinary tract tumours. We published our initial results in 2010. We think that our recent audit is quite encouraging. PDD ureterorenoscopy resulted in detection of additional urothelial tumours that could have been missed by the conventional white-light endoscopy. We suggest that this technique should be used in large multicentre trials to replicate our results.
Objective: • To evaluate the diagnostic accuracy of photodynamic diagnostic ureterorenoscopy after oral administration of 5-aminolevulinic acid (5-ALA) for upper urinary tract urothelial cancers.
Patients and methods: • In this audit, twenty-six patients underwent thirty-nine procedures (cystoscopy/ureterorenoscopy) following oral administration of 5-ALA for photodynamic diagnosis (PDD). • Twenty mg/kg body weight of 5-ALA was given orally 3-4 hours prior to the planned endoscopic visualisation. • Following standard white light cystoscopy and ureterorenoscopy, photodynamic diagnostic endoscopy was performed using D-light system (Olympus PDD cystoscope and 7.5Fr KARL STORZ PDD Flex-X ureterorenoscope) to detect fluorescence. • Biopsies were carried out from all suspicious areas, noting if lesions were detected under white or blue light or both.
Results: • A total of sixty-two biopsies were performed for suspicious urothelial lesions (35 bladder, 26 ureter/renal pelvis and 1 from prostatic urethra). • Of the 35 bladder biopsies, 11 lesions were seen under both white and blue light and 91% of these were malignant. • While 24 (68.5%) biopsies were taken from lesions seen only under blue light and 45.8% of these were malignant. • Similarly, of the 26 ureteric/renal pelvicalyceal biopsies, 11 were concurrent in both white and blue light and 100% of these were malignant. • While 10 (38.5%) lesions were seen only under blue light and 70% of these were malignant.
Conclusions: • Photodynamic diagnosis using oral 5-ALA is safe and feasible with additional advantages of detecting lesions not visualised with conventional white light endoscopy. • This may translate into more complete treatment thereby decreasing subsequent recurrences and possibly progression of the upper urinary tract urothelial cancers.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.
Similar articles
- Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
Ray ER, Chatterton K, Khan MS, Thomas K, Chandra A, O'Brien TS. Ray ER, et al. BJU Int. 2009 May;103(10):1363-7. doi: 10.1111/j.1464-410X.2008.08238.x. Epub 2008 Dec 8. BJU Int. 2009. PMID: 19076151 - Photodynamic diagnosis (PDD) for upper urinary tract transitional cell carcinoma (UT-TCC): evolution of a new technique.
Somani BK, Moseley H, Eljamel MS, Nabi G, Kata SG. Somani BK, et al. Photodiagnosis Photodyn Ther. 2010 Mar;7(1):39-43. doi: 10.1016/j.pdpdt.2009.12.005. Epub 2010 Jan 15. Photodiagnosis Photodyn Ther. 2010. PMID: 20230992 - 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma ∼Preliminary prospective single centre trial∼.
Fukuhara H, Kurabayashi A, Furihata M, Setuda S, Takahashi K, Murakami K, Tanaka T, Inoue K. Fukuhara H, et al. Photodiagnosis Photodyn Ther. 2020 Mar;29:101617. doi: 10.1016/j.pdpdt.2019.101617. Epub 2019 Dec 16. Photodiagnosis Photodyn Ther. 2020. PMID: 31857216 - Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy.
Zaak D, Karl A, Knüchel R, Stepp H, Hartmann A, Reich O, Bachmann A, Siebels M, Popken G, Stief C. Zaak D, et al. BJU Int. 2005 Aug;96(2):217-22. doi: 10.1111/j.1464-410X.2005.05604.x. BJU Int. 2005. PMID: 16001963 Review. - Novel endoscopic diagnosis for bladder cancer.
Lerner SP, Goh A. Lerner SP, et al. Cancer. 2015 Jan 15;121(2):169-78. doi: 10.1002/cncr.28905. Epub 2014 Aug 5. Cancer. 2015. PMID: 25132313 Review.
Cited by
- Diagnostic performance of photodynamic diagnosis with oral 5-aminolevulinic acid for upper tract- and bladder urothelial carcinoma: a single-centre, retrospective analysis.
Sano T, Yoshida T, Nakamoto T, Ohe C, Taniguchi H, Yanishi M, Kinoshita H. Sano T, et al. World J Urol. 2024 Jul 10;42(1):389. doi: 10.1007/s00345-024-05083-1. World J Urol. 2024. PMID: 38985343 - Diagnosing upper tract urothelial carcinoma: A review of the role of diagnostic ureteroscopy and novel developments over last two decades.
Gravestock P, Cullum D, Somani B, Veeratterapillay R. Gravestock P, et al. Asian J Urol. 2024 Apr;11(2):242-252. doi: 10.1016/j.ajur.2022.08.003. Epub 2022 Sep 23. Asian J Urol. 2024. PMID: 38680592 Free PMC article. Review. - Current Strategies in Photodynamic Therapy (PDT) and Photodynamic Diagnostics (PDD) and the Future Potential of Nanotechnology in Cancer Treatment.
Olszowy M, Nowak-Perlak M, Woźniak M. Olszowy M, et al. Pharmaceutics. 2023 Jun 12;15(6):1712. doi: 10.3390/pharmaceutics15061712. Pharmaceutics. 2023. PMID: 37376160 Free PMC article. Review. - 5-Aminolevulinic Acid-Induced Protoporphyrin IX Fluorescence Imaging for Tumor Detection: Recent Advances and Challenges.
Harada Y, Murayama Y, Takamatsu T, Otsuji E, Tanaka H. Harada Y, et al. Int J Mol Sci. 2022 Jun 9;23(12):6478. doi: 10.3390/ijms23126478. Int J Mol Sci. 2022. PMID: 35742921 Free PMC article. Review. - Differences in 5-Aminolevulinic Acid-Induced Hemodynamic Changes between Patients Undergoing Neurosurgery and Urological Surgery.
Shiratori T, Hotta K, Satoh M, Sato A, Kamigaito T, Kiuchi C, Tanaka R. Shiratori T, et al. JMA J. 2021 Oct 15;4(4):374-386. doi: 10.31662/jmaj.2021-0092. Epub 2021 Sep 27. JMA J. 2021. PMID: 34796292 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical